FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a$25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resista ...